Skip to main content

Ambev S.A. (ABEV) Stock Forecast

Data as of Aug 7, 2026

Consumer Defensive · Current price $3.02 (-0.50%)

Consensus Target
$3.20
Upside
+2.7%
Analysts
4
Rating
Sell(4.00)

Price Target Range

Low $2.90Consensus $3.20High $3.50
▲ Current $3.02

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

Consensus
Sell
Strong Buy0
Buy0
Hold0
Sell1
Strong Sell0

6-Month Trend

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

No analyst price targets available.

ABEV vs Sector & Market

MetricABEVConsumer Defensive AvgLarge Cap Avg
Analyst Rating4.002.552.42
Analyst Count41018
Target Upside+2.7%+1235.2%+17.2%
P/E Ratio14.6710.7735.26

Revenue Estimates

PeriodLowAvgHigh#
2026-09-30$22.39B$22.58B$22.92B1
2026-12-31$26.32B$26.54B$26.94B1
2027-03-31$18.64B$18.80B$19.08B1
2027-06-30$26.49B$26.72B$27.12B1
2027-09-30$26.82B$27.05B$27.46B1
2027-12-31$27.15B$27.39B$27.80B1

EPS Estimates

PeriodLowAvgHigh#
2026-09-30$0.25$0.25$0.261
2026-12-31$0.32$0.32$0.331
2027-03-31$0.26$0.27$0.271
2027-06-30$0.22$0.22$0.221
2027-09-30$0.27$0.27$0.281
2027-12-31$0.34$0.34$0.351

Frequently Asked Questions

What is the analyst consensus for ABEV?

The consensus among 4 analysts covering Ambev S.A. (ABEV) is Sell with an average price target of $3.20.

What is the highest price target for ABEV?

The highest analyst price target for ABEV is $3.50.

What is the lowest price target for ABEV?

The lowest analyst price target for ABEV is $2.90.

How many analysts cover ABEV?

4 analysts have issued ratings for Ambev S.A. in the past 12 months.

Is ABEV a buy or sell right now?

Based on 4 analyst ratings, ABEV has a consensus rating of Sell (4.00/5) with a +2.7% upside to the consensus target of $3.20.

What are the earnings estimates for ABEV?

Analysts estimate ABEV will report EPS of $0.25 for the period ending 2026-09-30, with revenue estimated at $22.58B.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.